CSL Behring Discontinues Monoclate-P® Production
March 6, 2018
CSL Behring has made the decision to discontinue Monoclate-P®, antihemophilic factor (human), factor VIII. According to the manufacturer, "as hemophilia A treatment has advanced, and patients have transitioned from plasma-derived to recombinant and longer-acting therapies, it has been increasingly difficult to sustain the production and distribution of Monoclate-P."
CSL estimates that supply will be available through December 2018, which gives you time to consider different treatment options for your patients.
FFF is Here to Help
Due to this recent information regarding Monoclate-P, we recognize you may need to seek out and order an alternative coagulation product. FFF is ready to help and have the following options available to meet your factor VIII patient needs.
Product |
Manufacturer |
Factor VIII (Recombinant) |
|
Shire |
|
CSL Behring |
|
Bayer |
|
Bayer |
|
Novo Nordisk |
|
Octapharma |
|
Shire |
|
Pfizer |
|
Pfizer |
|
Factor VIII (Recombinant), Long-Acting |
|
Shire |
|
CSL Behring |
|
Bioverativ |
|
Factor VIII (Human) |
|
Shire |
|
Kedrion |
|
Factor VIII/von Willebrand Factor Complex (Human) |
|
Grifols |
|
CSL Behring |
|
Octapharma |
If you have any questions or need assistance,
please call your FFF Sales Representative or Wow! Customer Care at (800) 843-7477.